Ticker brief

AVBP ARRIVENT BIOPHARMA INC

Consumer, Non-cyclical · Biotechnology

last close
$21.00
1 day
+9.4%
14 days
+25.5%
mkt cap
·
signals 14d
24
authors 14d
16
crowd 14d
-0.5σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-13 · now +0.12 (−1 bearish … +1 bullish)
Who spoke16
authorgradetrader scoresignalsmean sent
@BiopharmIQB·5-0.50
@BioStocksC-1.772-0.45
@PrismMarketViewC·2-0.33
@TickeronC+1.532-0.53
@zohmbasticC-2.942+0.28
@adamfeuersteinA-1.031-0.80
@fwpharmaB-1.911-0.60
@newsinvestingC·1-0.60
@BPharmCatalystC·1-0.65
@OpenOutcrierC·1-0.70
@dagoongloveB+0.511-0.70
@UTEX_ioC+0.041-0.65
@TWFeditorC-1.361-0.65
@wliangC-2.481-0.30
@TheNewMoney_appC·1+0.65
@OzmosiHealthC·1+0.25
Recent signals24of 24 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-13@zohmbastic+0.30Reports a 13G disclosing 2.47M shares and a 5% stake.+30.5%
2026-10-13@BiopharmIQ+0.10Biotech opening-news board pairs catalysts with contemporaneous price moves.+30.5%
2026-10-13@PrismMarketView-0.05Reports index addition while noting a Phase 3 program missed its primary endpoint.+30.5%
2026-10-12@OzmosiHealth+0.25ArriVent dosed the first patient with its novel dual-target ADC.+27.6%
2026-10-09@BiopharmIQ-0.60Summarizes large biotech moves tied to a buyout and trial outcomes, then flags upcoming studies.+25.5%
2026-10-09@BiopharmIQ-0.60Weekly biotech event roundup covering acquisition, clinical data, FDA status, licensing, and a trial miss.+25.5%
2026-10-07@Tickeron-0.25A failed Phase 3 endpoint and slashed targets weigh against pipeline and cash support.+24.3%
2026-10-07@zohmbastic+0.25Notes an AVBP bounce, with the chart needed for detail.+24.3%
2026-10-06@TheNewMoney_app+0.65Reports AVBP options volume up 956% versus average with 92% calls.+39.2%
2026-10-06@wliang-0.30Notes ARKG down about 8% on AVBP news but expects a bounce from support.+39.2%
2026-10-06@BiopharmIQ-0.70Reports sharp opening declines tied to a Phase 3 update, interim data and an equity raise.+39.2%
2026-10-06@BiopharmIQ-0.70Biotech mover list quantifies the largest negative opening reactions and their associated catalysts.+39.2%
2026-10-06@Tickeron-0.80Reports a pivotal Phase 3 trial missing its primary endpoint, driving a 54.18% plunge.+39.2%
2026-10-06@TWFeditor-0.65Characterizes AVBP's trading day as calamitous.+39.2%
2026-10-06@UTEX_io-0.65Phase 3 cancer trial failed its primary endpoint, prompting a sharp decline.+39.2%
2026-10-06@dagoonglove-0.70AVBP's FURVENT phase 3 missed its primary endpoint, undermining investment appeal.+39.2%
2026-10-06@OpenOutcrier-0.70Reports ArriVent's trial missing its primary endpoint and the stock tumbling about 60%.+39.2%
2026-10-06@BPharmCatalyst-0.65AVBP's Phase 3 FURVENT trial missed its primary PFS endpoint with p=0.0654.+39.2%
2026-10-06@newsinvesting-0.60An ArriVent clinical trial missed its primary endpoint.+39.2%
2026-10-06@PrismMarketView-0.60Lists premarket gainers and decliners with percentage moves.+39.2%
2026-10-06@fwpharma-0.60ArriVent's firmonertinib misses the primary endpoint in a lung-cancer study.+39.2%
2026-10-06@adamfeuerstein-0.80AVBP's exon20 lung-cancer drug failed to improve progression-free survival in a phase 3 study.+39.2%
2026-10-06@BioStocks-0.65AVBP's Phase 3 FURVENT trial failed its primary endpoint.+39.2%
2026-10-06@BioStocks-0.25Reports a trading halt in AVBP.+39.2%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.